| Highly reactive oxygen species: detection, formation, and possible functions W Freinbichler, MA Colivicchi, C Stefanini, L Bianchi, C Ballini, B Misini, ... Cellular and molecular life sciences 68 (12), 2067-2079, 2011 | 253 | 2011 |
| Intrinsic subtype switching and acquired ERBB2/HER2 amplifications and mutations in breast cancer brain metastases N Priedigkeit, RJ Hartmaier, Y Chen, D Vareslija, A Basudan, RJ Watters, ... JAMA oncology 3 (5), 666-671, 2017 | 197 | 2017 |
| Transcriptome characterization of matched primary breast and brain metastatic tumors to detect novel actionable targets D Varešlija, N Priedigkeit, A Fagan, S Purcell, N Cosgrove, PJ O’Halloran, ... JNCI: Journal of the National Cancer Institute 111 (4), 388-398, 2019 | 135 | 2019 |
| Brain metastasis cell lines panel: a public resource of organotropic cell lines M Valiente, AED Van Swearingen, CK Anders, A Bairoch, A Boire, PD Bos, ... Cancer research 80 (20), 4314-4323, 2020 | 115 | 2020 |
| Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism C Monteiro, L Miarka, M Perea-García, N Priego, P Garcia-Gomez, ... Nature medicine 28 (4), 752-765, 2022 | 85 | 2022 |
| Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities N Cosgrove, D Varešlija, S Keelan, A Elangovan, JM Atkinson, ... Nature communications 13 (1), 514, 2022 | 77 | 2022 |
| 6-Hydroxydopamine: A far from simple neurotoxin D Varešlija, KF Tipton, GP Davey, AG McDonald Journal of Neural Transmission 127 (2), 213-230, 2020 | 73 | 2020 |
| AIB1: ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells J O'Hara, D Vareslija, J McBryan, F Bane, P Tibbitts, C Byrne, RM Conroy, ... Clinical Cancer Research 18 (12), 3305-3315, 2012 | 51 | 2012 |
| FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues A Font-Tello, N Kesten, Y Xie, L Taing, D Varešlija, LS Young, AA Hamid, ... Nature Protocols, 1-16, 2020 | 38 | 2020 |
| Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer. YLS Browne AL, Charmsaz S, Varešlija D, Fagan A, Cosgrove N, Cocchiglia S ... Oncogene, 2018 | 37 | 2018 |
| A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival A Giannoudis, K Clarke, R Zakaria, D Varešlija, M Farahani, L Rainbow, ... Scientific Reports 9 (1), 18518, 2019 | 36 | 2019 |
| Transcriptomic profiling of sequential tumors from breast cancer patients provides a global view of metastatic expression changes following endocrine therapy J McBryan, A Fagan, D McCartan, FT Bane, D Varešlija, S Cocchiglia, ... Clinical Cancer Research 21 (23), 5371-5379, 2015 | 34 | 2015 |
| Adaptation to AI therapy in breast cancer can induce dynamic alterations in ER activity resulting in estrogen-independent metastatic tumors D Varešlija, J McBryan, A Fagan, AM Redmond, Y Hao, AH Sims, ... Clinical Cancer Research 22 (11), 2765-2777, 2016 | 33 | 2016 |
| A clinically compatible drug‐screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis L Zhu, D Retana, P García‐Gómez, L Álvaro‐Espinosa, N Priego, ... EMBO molecular medicine 14 (3), e14552, 2022 | 32 | 2022 |
| PARP inhibitors in breast cancer: a short communication GR Daly, MM AlRawashdeh, J McGrath, GP Dowling, L Cox, S Naidoo, ... Current Oncology Reports 26 (2), 103-113, 2024 | 26 | 2024 |
| Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression A Giannoudis, D Varešlija, V Sharma, R Zakaria, A Platt-Higgins, ... ESMO open 7 (6), 100636, 2022 | 26 | 2022 |
| Epigenome-wide SRC-1–mediated gene silencing represses cellular differentiation in advanced breast Cancer E Ward, D Varešlija, S Charmsaz, A Fagan, AL Browne, N Cosgrove, ... Clinical Cancer Research 24 (15), 3692-3703, 2018 | 24 | 2018 |
| Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic … D Varešlija, E Ward, SP Purcell, NS Cosgrove, S Cocchiglia, ... Oncogene 40 (7), 1318-1331, 2021 | 22 | 2021 |
| BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer L Walsh, KE Haley, B Moran, B Mooney, F Tarrant, SF Madden, ... Clinical Cancer Research 25 (23), 7139-7150, 2019 | 21 | 2019 |
| Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity S Prekovic, T Chalkiadakis, M Roest, D Roden, C Lutz, K Schuurman, ... EMBO Molecular Medicine 15 (12), e17737, 2023 | 20 | 2023 |
Leonie YoungRoyal College of Surgeons in IrelandVerified email at rcsi.ie
